Table 5: Association of MnSOD Ala16Val polymorphism
with Diabetic retinopathy, nephropathy and cardiovascular complications.
Chi-square test was used to determine significance at P < 0.05.
Type
2 diabetic patients |
Genotype |
p-Value |
OR
(95% CI) |
|||
CC (Ala) (n = 6) |
CT (Ala/Val) (n = 29) |
TT (Val) (n = 24) |
||||
DR+ (n = 16) |
1/16 (6.3%) |
5/16 (31.3%) |
10/16 (62.5%) |
0.115 |
1.92 (1.082-3.84) |
|
DR- (n = 43) |
5/43 (11.6%) |
24/43 (55.8%) |
14/43 (32.6%) |
|||
DP+ (n = 5) |
0/5 (0%) |
2/5 (40%) |
3/5 (60%) |
0.563 |
1.543 (0.7-3.39) |
|
DP- (n = 56) |
6/56 (11.1%) |
27/56 (50%) |
21/56 (38.9%) |
|||
CVD+ (n = 8) |
0/8 (0%) |
3/8 (37.5%) |
5/8 (62.5 %) |
0.320 |
1.678 (0.881-3.995) |
|
CVD- (n = 51) |
6/51 (11.8%) |
26/51 (51%) |
19/51 (37.3%) |
|||
DR+: presence of diabetic retinopathy; DR-: no diabetic
retinopathy; DP+: presence of nephropathy; DP-: no nephropathy; CVD+: presence
of cardiovascular complications; CVD-: no cardiovascular complications.